 Pravastatin
"Pravastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
| Descriptor ID |
D017035
|
| MeSH Number(s) |
D02.455.426.559.847.638.930 D04.615.638.930
|
| Concept/Terms |
Vasten- Vasten
- Aventis Brand of Pravastatin Sodium
Lin-Pravastatin- Lin-Pravastatin
- Lin Pravastatin
- Linson Pharma Brand of Pravastatin Sodium
Lipemol- Lipemol
- Squibb Brand of Pravastatin Sodium
Liplat- Liplat
- Esteve Brand of Pravastatin Sodium
Nu-Pravastatin- Nu-Pravastatin
- Nu Pravastatin
- Nu-Pharma Brand of Pravastatin Sodium
Prareduct- Prareduct
- Sankyo Brand of Pravastatin Sodium
- Mevalotin
Pravachol- Pravachol
- Elisor
- Selektine
- Pravacol
- Pravasin
- Bristol-Myers Squibb Brand of Pravastatin Sodium
- Lipostat
SQ-31000- SQ-31000
- SQ 31000
- SQ31000
- SQ-31,000
- SQ 31,000
- SQ31,000
Apo-Pravastatin- Apo-Pravastatin
- Apo Pravastatin
- Apotex Brand of Pravastatin Sodium
Bristacol- Bristacol
- Juste Brand of Pravastatin Sodium
|
Below are MeSH descriptors whose meaning is more general than "Pravastatin".
Below are MeSH descriptors whose meaning is more specific than "Pravastatin".
This graph shows the total number of publications written about "Pravastatin" by people in this website by year, and whether "Pravastatin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pravastatin" by people in Profiles.
-
Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009 Oct 28; 29(43):13543-56.
-
Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005 Oct; 16(10):1272-6.
-
Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis. 2004 Nov; 177(1):77-81.
-
Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond). 2004 Feb; 106(2):215-7.
-
Liebson PR. LIFE and ARBITER. Prev Cardiol. 2003; 6(2):108-11.
-
Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis. 2001 Apr; 155(2):463-6.
-
Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 Mar 20; 353(9157):983-4.
-
Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998 May 27; 279(20):1643-50.
-
Rosenson RS, Tangney CC. Beneficial effects of statins. Lancet. 1996 Dec 07; 348(9041):1583.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|